BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7516190)

  • 1. Failure of combination therapy with recombinant granulocyte colony-stimulating factor and erythropoietin in myelodysplastic syndromes.
    Imamura M; Kobayashi M; Kobayashi S; Yoshida K; Mikuni C; Ishikawa Y; Matsumoto S; Sakamaki S; Niitsu Y; Hinoda Y
    Ann Hematol; 1994 Apr; 68(4):163-6. PubMed ID: 7516190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin.
    Mantovani L; Lentini G; Hentschel B; Wickramanayake PD; Loeffler M; Diehl V; Tesch H
    Br J Haematol; 2000 May; 109(2):367-75. PubMed ID: 10848827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in aplastic anemia.
    Imamura M; Kobayashi M; Kobayashi S; Yoshida K; Mikuni C; Ishikawa Y; Matsumoto S; Sakamaki S; Niitsu Y; Hinoda Y
    Am J Hematol; 1995 Jan; 48(1):29-33. PubMed ID: 7530405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical efficacy analysis of recombinant human erythropoietin in the treatment of lower-risk myelodysplastic syndromes].
    Zhang H; Qin T; Xu Z; Fang L; Pan L; Hu N; Qu S; Zhang Y; Xiao Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):18-23. PubMed ID: 24602726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of recombinant human G-CSF combined with EPO in treatment of patients with MDS].
    Li ZY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):512-3. PubMed ID: 15972155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin.
    Economopoulos T; Mellou S; Papageorgiou E; Pappa V; Kokkinou V; Stathopoulou E; Pappa M; Raptis S
    Leukemia; 1999 Jul; 13(7):1009-12. PubMed ID: 10400415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin, with and without granulocyte-colony stimulating factor (G-CSF), in the treatment of myelodysplastic syndrome (MDS) patients.
    Miller K
    Leuk Res; 1998 May; 22 Suppl 1():S13-6. PubMed ID: 9734694
    [No Abstract]   [Full Text] [Related]  

  • 9. Hematologic response in patients with aplastic anemia after long-term administration of recombinant human granulocyte colony-stimulating factor and erythropoietin.
    Yonekura S; Kawada H; Watanabe S; Masumoto A; Ogawa Y; Fukuda R; Nishihira H; Matsuyama S; Katoh S; Mouri H; Motomura S; Shionoya S; Hotta T
    Clin Ther; 1997; 19(6):1394-407. PubMed ID: 9444448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group.
    Thompson JA; Gilliland DG; Prchal JT; Bennett JM; Larholt K; Nelson RA; Rose EH; Dugan MH
    Blood; 2000 Feb; 95(4):1175-9. PubMed ID: 10666187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin.
    Negrin RS; Stein R; Vardiman J; Doherty K; Cornwell J; Krantz S; Greenberg PL
    Blood; 1993 Aug; 82(3):737-43. PubMed ID: 7687889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy.
    Negrin RS; Stein R; Doherty K; Cornwell J; Vardiman J; Krantz S; Greenberg PL
    Blood; 1996 May; 87(10):4076-81. PubMed ID: 8639764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol.
    Ganser A; Maurer A; Contzen C; Seipelt G; Ottmann OG; Schadeck-Gressel C; Kolbe K; Haas R; Zander C; Reutzel R; Hoelzer D
    Ann Hematol; 1996 Apr; 72(4):237-44. PubMed ID: 8624378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes.
    Hansen PB; Johnsen HE; Hippe E; Hellström-Lindberg E; Ralfkiaer E
    Am J Hematol; 1993 Dec; 44(4):229-36. PubMed ID: 8237992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes.
    Yoshida Y; Hirashima K; Asano S; Takaku F
    Br J Haematol; 1991 Jul; 78(3):378-84. PubMed ID: 1714759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia.
    Bessho M; Jinnai I; Hirashima K; Saito M; Murohashi I; Ino H; Tsuji M; Fukuda M; Maruyama M; Kusumoto S
    Stem Cells; 1994 Nov; 12(6):604-15. PubMed ID: 7533579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dramatic hyperleukocytosis after treatment of myelodysplastic syndrome with pegfilgrastim and darbepoetin-alfa.
    Heydrich BN; Schoch R; Horst HA; Kneba M
    Ann Hematol; 2008 Jan; 87(1):77-8. PubMed ID: 17710399
    [No Abstract]   [Full Text] [Related]  

  • 19. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial.
    Casadevall N; Durieux P; Dubois S; Hemery F; Lepage E; Quarré MC; Damaj G; Giraudier S; Guerci A; Laurent G; Dombret H; Chomienne C; Ribrag V; Stamatoullas A; Marie JP; Vekhoff A; Maloisel F; Navarro R; Dreyfus F; Fenaux P
    Blood; 2004 Jul; 104(2):321-7. PubMed ID: 15054036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined use of erythropoietin and G-CSF in the treatment of myelodysplastic syndromes.
    Haematologica; 1999 Dec; 84(12):1057. PubMed ID: 10586204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.